生长抑素受体靶向PET/CT在小细胞肺癌患者治疗决策与疾病控制中的应用
回顾性分析100例小细胞肺癌患者,评估生长抑素受体靶向PET/CT对治疗决策的影响及与生存的关系。PET/CT后59%患者治疗改变(主要为肽受体放射性核素治疗),53例随访者中26.4%达疾病控制,但治疗改变未显著延长生存。
要点
- 生长抑素受体PET/CT在39处骨病灶评估中19处(49%)优于CT。
- 100例中59例(59%)治疗后方案改变,其中28/44(63.6%)接受肽受体放射性核素治疗。
- 治疗改变者与未改变者生存无显著差异(155天 vs 171天,HR 0.94;210天 vs 171天,HR 0.67)。
核心结论
- 在小细胞肺癌患者中,生长抑素受体靶向混合影像提供疾病状态的补充信息。
- PET/CT使59%患者治疗管理改变(主要为肽受体放射性核素治疗),超过26%达到疾病控制。
- 高比例患者计划接受肽受体放射性核素治疗,可能为联合策略(如肽受体放射性核素治疗联合新近引入的RNA聚合酶II抑制剂)实现协同抗肿瘤效应奠定基础。
研究设计与样本
- 回顾性研究,纳入100例接受生长抑素受体PET/CT的小细胞肺癌患者。
- 评估PET与CT的诊断性能,比较PET/CT前后的治疗以确定分子影像对治疗决策的影响。
- 确定治疗修改后的疾病控制率,并评估治疗改变与未改变患者的生存。
主要发现
- 相对于CT,生长抑素受体PET alone在39处骨病灶评估中19处(49%)更优。
- 100例中59例(59%)在生长抑素受体PET/CT后治疗改变;59例中40例(74.6%)接受全身治疗,15例(25.4%)计划非全身治疗。
- 非全身治疗组15例中13例(86.7%)接受局部放疗或积极监测(2/15,13.3%)。
- 计划全身治疗者中,44例中28例(63.6%)接受肽受体放射性核素治疗,10例(22.7%)化疗,3例(6.8%)更改化疗方案,3例(6.8%)启动酪氨酸激酶抑制剂。
- 治疗改变者中53例有随访,14例(26.4%)达到疾病控制;与未改变者(171天)相比,改为全身治疗(155天;HR 0.94;95%CI 0.53-1.67)或非全身治疗(210天;HR 0.67;95%CI 0.34-1.34)均未延长生存(P≥0.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Somatostatin receptor (SSTR)-targeted PET/CT is used for patients affected with small cell lung cancer (SCLC), but the clinical impact has not been elucidated yet. We aimed to determine whether SSTR PET/CT can trigger relevant therapeutic management changes in patients with SCLC and whether those modifications achieve disease control and are associated with prolonged survival. METHODS: One hundred patients with SCLC received SSTR PET/CT. In a retrospective setting, we evaluated the diagnostic performance of PET versus CT and compared therapies before and after PET/CT to determine the impact of molecular imaging on treatment decision. We also determined the rate of disease control after therapeutic modifications and assessed survival in patients with and without changes in the therapeutic regimen. RESULTS: Relative to CT, SSTR PET alone was superior for assessing bone lesions in 19 of 39 instances (49%). Treatment was modified in 59 of 100 (59%) after SSTR PET/CT. Forty of 59 (74.6%) received systemic treatment after hybrid imaging, with the remaining 15 of 59 (25.4%) scheduled for nonsystemic therapy. In the latter group, 13 of 15 (86.7%) received local radiation therapy or active surveillance (2/15 [13.3%]). Individuals scheduled for systemic treatment after imaging received peptide receptor radionuclide therapy (PRRT) in 28 of 44 (63.6%), followed by chemotherapy in 10 of 44 (22.7%), change in chemotherapy regimen in 3 of 44 (6.8%), and initiation of tyrosine kinase inhibitor in the remaining 3 of 44 (6.8%). Among patients with modified treatment, follow-up was available in 53 subjects, and disease control was achieved in 14 of 53 (26.4%). However, neither change to systemic treatment (155 days; hazard ratio, 0.94; 95% confidence interval, 0.53-1.67) nor change to nonsystemic treatment (210 days; hazard ratio, 0.67; 95% confidence interval, 0.34-1.34) led to a prolonged survival when compared with subjects with no change (171 days, P ≥ 0.22, respectively). CONCLUSIONS: In patients with SCLC, SSTR-targeted hybrid imaging provides complementary information on the disease status. PET/CT led to management changes in 59% (mainly PRRT), achieving disease control in >26%. The high fraction of patients scheduled for PRRT may lay the foundation for combination strategies to achieve synergistic antitumor effects, for example, by combining PRRT plus recently introduced RNA polymerase II inhibitors.
引用
- Serfling SE, Hartrampf PE, Zhi Y, et al. Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer. Clin Nucl Med. 2023. PMID: 36754127. doi:10.1097/RLU.0000000000004591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。